Expression of MECOM is associated with unfavorable prognosis in glioblastoma multiforme.
BACKGROUND
MDS1 and EVI1 complex locus protein EVI1 (MECOM) is an oncogenic transcription factor in several kinds of cancers. However, the clinical significance of MECOM in glioblastoma multiforme (GBM) has not been well elucidated.


PATIENTS AND METHODS
Our study enrolled 86 resected samples of GBM in three medical centers. We detected the expression of MECOM in all the 86 samples by immunohistochemistry and compared the difference of MECOM mRNA between tumor tissues and adjacent tissues with real-time polymerase chain reaction. With immunoblotting, we detected the MECOM expression in different GBM cell lines. Moreover, we analyzed the correlation between MECOM expression and clinicopathologic factors with chi-square test, and evaluated the prognostic value of MECOM with univariate and multivariate analysis.


RESULTS
In GBM tissue, the percentage of MECOM high expression is 41.9% (36/86). The mRNA of MECOM in tumor tissues is remarkably higher than that in adjacent tissues, indicating the oncogenic role of MECOM in GBM. MECOM exists in all the detected cell lines with different abundance. Moreover, MECOM is correlated with poorer overall survival rate (P=0.033) and can be identified as an independent prognostic factor in GBM (P=0.042).


CONCLUSION
MECOM could be considered as an independent prognostic factor in GBM, predicting it as a potential and promising molecular drug target.
['Hou|Aiwu|A|', 'Zhao|Lizhen|L|', 'Zhao|Fuzhen|F|', 'Wang|Weiliang|W|', 'Niu|Jianyi|J|', 'Li|Bingxuan|B|', 'Zhou|Zhongjin|Z|', 'Zhu|Dongyuan|D|']
MECOM prognosis glioblastoma multiforme progression